DEC 23, 2019 8:08 AM PST

FDA Approves New Schizophrenic Drug

WRITTEN BY: Nouran Amin

The US Food and Drug Administration (FDA) has approved an atypical antipsychotic Caplyta (lumateperone; Intra-Cellular Therapies) for the treating schizophrenia in adult patients.

Confirmation to market the drug comes from two double-blinded studies that evaluated Caplyta in schizophrenic patients for 28 days. Results were affirming and showed the taking 42mg of Caplyta daily was enough to reduce schizophrenic symptoms from baseline to Day 28.

Learn more about schizophrenia:

Like every other drug, safety is a priority Caplyta is no exception. The drug comes with a boxed warning for increased mortality rates among elderly patients receiving the medication for dementia-related psychosis. The most persist side-effects was sedation and dry mouth.

“Schizophrenia is a complex disease that severely impacts patients and their families,” said Jeffrey A. Lieberman, MD, Lawrence C. Kolb Professor and Chairman of Psychiatry, Columbia University, College of Physicians and Surgeons and Director, New York State Psychiatric Institute. “Effective treatment provided in a timely fashion can be game-changing for people living with schizophrenia. The efficacy and safety profile of Caplyta approved by the FDA, offers healthcare providers an important new option for treating people living with schizophrenia.”

How does Caplyta work? The exact mechanism remains a mystery but it is generally believed to work its magic by antagonizing the activity of particular serotonin receptors known the 5-HT2A and the postsynaptic activity of the central dopamine D2 receptors.

Caplyat will be marketed in 42mg capsules provided in 30-count boxes.

Source: IntraCellularTherapies

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 14, 2021
Cancer
Cell Viability- Where to Begin?
APR 14, 2021
Cell Viability- Where to Begin?
Written By: Author As I pondered the title of this article, my thoughts immediately went back to a request by my Ph.D. a ...
APR 17, 2021
Drug Discovery & Development
Facebook AI May Speed up Cancer Drug Discovery
APR 17, 2021
Facebook AI May Speed up Cancer Drug Discovery
Facebook has claimed that its new artificial intelligence, known as 'Compositional Perturbation Autoencoder' (CP ...
APR 12, 2021
Drug Discovery & Development
Epidural Use Not Linked To Autism
APR 12, 2021
Epidural Use Not Linked To Autism
Epidurals are a form of pain relief during childbirth and is used by more than half of all women in labor. Many women wh ...
APR 22, 2021
Drug Discovery & Development
New Method To Fast Track Drug Development
APR 22, 2021
New Method To Fast Track Drug Development
The time it takes to respond to disease outbreaks is critical. But designing drugs to combat these disease outbreaks is ...
JUN 14, 2021
Microbiology
Researchers Identify a Novel, Beneficial Bacterium
JUN 14, 2021
Researchers Identify a Novel, Beneficial Bacterium
Since researchers were able to use genetic technologies to reveal how important the gut microbiome is to human health, t ...
JUN 26, 2021
Cannabis Sciences
CBD Shows Promise for Lowering Blood Sugar
JUN 26, 2021
CBD Shows Promise for Lowering Blood Sugar
Whether or not cannabis can help manage symptoms of diabetes is unclear. While some studies support cannabis as a potent ...
Loading Comments...